This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
This week we discuss cluster RCTs. How do you conduct, consent, analyse and interpret these? Why do you do cluster RCTs? Let’s discuss using the Dial-Mag trial as an example.
This week, we will discuss the NEJM cluster RCT from Victor and colleagues, which has created such a buzz. Barbers and pharmacists team to have a fantastic effect. Could it be true?
March 13/14 we will discuss the pair of trials in NEJM from Vanderbilt: comparing balanced solutions to normal saline in critically ill & not ill patients. Join us for the next #NephJC to parse through SMART & SALT-ED